{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:57:44Z","timestamp":1788519464137,"version":"build-2803163510"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Japan Society for the Promotion of Science (JSPS) KAKENHI","award":["21H04754"],"award-info":[{"award-number":["21H04754"]}]},{"name":"Japan Society for the Promotion of Science (JSPS) KAKENHI","award":["25H00963"],"award-info":[{"award-number":["25H00963"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,12,23]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Canine oral malignant melanoma (OMM) is a highly aggressive tumor, with several available treatment options, though few achieve durable response or complete remission. Because of its biological similarity to human mucosal melanoma, canine OMM represents a valuable spontaneous model for translational immunotherapy studies. Anti-programmed cell death protein 1 (PD-1) antibody therapy has shown promise in canine OMM; however, predictive biomarkers for treatment response and survival have not been identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter, prospective, investigator-initiated clinical trial to evaluate the safety and efficacy of a caninized anti-canine PD-1 monoclonal antibody (ca-4F12-E6) in 150 dogs with advanced OMM. The dogs were administered 3\u2009mg\/kg ca-4F12-E6 intravenously every 2\u2009weeks. Treatment response was assessed using cRECIST V.1.0. Biomarker analyses included peripheral blood parameters, cytokine\/chemokines, peripheral lymphocyte subsets, microsatellite instability (MSI), immunohistochemistry for immune cell and mismatch repair protein markers, and RNA sequencing of the tumor tissue. Associations with clinical outcomes were determined by logistic regression and Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall response rate was 14.7%, with a best overall response rate of 16.7%. Treatment-related adverse events occurred in 40.0% of the dogs, which were primarily grade 1\u20133. Increased baseline white blood cell, neutrophil count, and C reactive protein levels were significantly associated with poor response, shorter progression-free survival, and reduced overall survival (OS). MSI-high tumors were associated with significantly prolonged OS compared with MSI-low\/microsatellite stable tumors. Transcriptome analysis revealed differentially expressed genes and enriched immune-related pathways in responders, though limited by sample size.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ca-4F12-E6 exhibited durable antitumor activity with manageable safety profile in dogs with OMM. Baseline systemic inflammatory markers and MSI status may serve as predictive biomarkers for clinical outcomes. The results support the use of canine OMM as a comparative model for human immuno-oncology and biomarker discovery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013623","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T02:25:17Z","timestamp":1769135117000},"page":"e013623","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Caninized PD-1 monoclonal antibody in oral malignant melanoma: efficacy and exploratory biomarker analysis"],"prefix":"10.1136","volume":"14","author":[{"given":"Masaya","family":"Igase","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan"},{"name":"Research Institute for Cell Design Medical Science, Yamaguchi University, Yamaguchi, Japan"},{"name":"Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation, Tokorozawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hagimori","sequence":"additional","affiliation":[{"name":"Kyoto Animal Medical Center, Kyoto, Japan"},{"name":"Kamogawa Animal Medical Center, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakuya","family":"Inanaga","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Mizoguchi","sequence":"additional","affiliation":[{"name":"Kamogawa Animal Medical Center, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Itamoto","sequence":"additional","affiliation":[{"name":"Research Institute for Cell Design Medical Science, Yamaguchi University, Yamaguchi, Japan"},{"name":"Laboratory of Veterinary Small Animal Clinical Science, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Research Institute for Cell Design Medical Science, Yamaguchi University, Yamaguchi, Japan"},{"name":"Laboratory of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Motegi","sequence":"additional","affiliation":[{"name":"Veterinary Clinical Genetics and Information, Cooperative Department of Veterinary Medicine, Tokyo University of Agriculture and Technology, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroka","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kato","sequence":"additional","affiliation":[{"name":"Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Shiga","sequence":"additional","affiliation":[{"name":"Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Tsukui","sequence":"additional","affiliation":[{"name":"Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation, Tokorozawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9580-7557","authenticated-orcid":false,"given":"Takuya","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan"},{"name":"Research Institute for Cell Design Medical Science, Yamaguchi University, Yamaguchi, Japan"},{"name":"Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation, Tokorozawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"2026012218251179000_14.1.e013623.1","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12185"},{"key":"2026012218251179000_14.1.e013623.2","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.2460\/javma.247.10.1146","article-title":"Outcomes of dogs undergoing radiotherapy for treatment of oral malignant melanoma: 111 cases (2006-2012)","volume":"247","author":"Kawabe","year":"2015","journal-title":"J Am Vet Med Assoc"},{"key":"2026012218251179000_14.1.e013623.3","doi-asserted-by":"publisher","DOI":"10.2460\/javma.2001.218.1444"},{"key":"2026012218251179000_14.1.e013623.4","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2024.1359426","article-title":"Melanoma of the dog and cat: consensus and guidelines","volume":"11","author":"Polton","year":"2024","journal-title":"Front Vet Sci"},{"key":"2026012218251179000_14.1.e013623.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"2026012218251179000_14.1.e013623.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694"},{"key":"2026012218251179000_14.1.e013623.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2407417"},{"key":"2026012218251179000_14.1.e013623.8","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-09444-2","article-title":"A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma","volume":"7","author":"Maekawa","year":"2017","journal-title":"Sci Rep"},{"key":"2026012218251179000_14.1.e013623.9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75533-4","article-title":"A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs","volume":"10","author":"Igase","year":"2020","journal-title":"Sci Rep"},{"key":"2026012218251179000_14.1.e013623.10","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2023.1144869","article-title":"Reversing stage III oral adenocarcinoma in a dog treated with anti-canine PD-1 therapeutic antibody: a case report","volume":"10","author":"Xu","year":"2023","journal-title":"Front Vet Sci"},{"key":"2026012218251179000_14.1.e013623.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2026012218251179000_14.1.e013623.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444."},{"key":"2026012218251179000_14.1.e013623.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"2026012218251179000_14.1.e013623.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"2026012218251179000_14.1.e013623.15","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356144","article-title":"Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients","volume":"7","author":"Xing","year":"2018","journal-title":"Oncoimmunology"},{"key":"2026012218251179000_14.1.e013623.16","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4466"},{"key":"2026012218251179000_14.1.e013623.17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2026012218251179000_14.1.e013623.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0864-3","article-title":"Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors","volume":"17","author":"Yi","year":"2018","journal-title":"Mol Cancer"},{"key":"2026012218251179000_14.1.e013623.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-13484-8","article-title":"Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy","volume":"12","author":"Maekawa","year":"2022","journal-title":"Sci Rep"},{"key":"2026012218251179000_14.1.e013623.20","doi-asserted-by":"crossref","DOI":"10.4142\/jvs.23144","article-title":"Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors","volume":"25","author":"Igase","year":"2024","journal-title":"J Vet Sci"},{"key":"2026012218251179000_14.1.e013623.21","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12677"},{"key":"2026012218251179000_14.1.e013623.22","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12032"},{"key":"2026012218251179000_14.1.e013623.23","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01051-z"},{"key":"2026012218251179000_14.1.e013623.24","doi-asserted-by":"crossref","first-page":"683419","DOI":"10.3389\/fonc.2021.683419","article-title":"FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"2026012218251179000_14.1.e013623.25","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/jvim.16454","article-title":"Relationship of microsatellite instability to mismatch repair deficiency in malignant tumors of dogs","volume":"36","author":"Inanaga","year":"2022","journal-title":"J Vet Intern Med"},{"key":"2026012218251179000_14.1.e013623.26","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.001561"},{"key":"2026012218251179000_14.1.e013623.27","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-14-219","article-title":"TCC: an R package for comparing tag count data with robust normalization strategies","volume":"14","author":"Sun","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"2026012218251179000_14.1.e013623.28","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"2026012218251179000_14.1.e013623.29","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13620"},{"key":"2026012218251179000_14.1.e013623.30","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1177\/03009858211022704","article-title":"Mismatch repair deficiency in canine neoplasms","volume":"58","author":"Inanaga","year":"2021","journal-title":"Vet Pathol"},{"key":"2026012218251179000_14.1.e013623.31","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2020.0002"},{"key":"2026012218251179000_14.1.e013623.32","first-page":"963","volume-title":"vivo (Athens, Greece)","volume":"25","author":"Carvalho","year":"2011"},{"key":"2026012218251179000_14.1.e013623.33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9258"},{"key":"2026012218251179000_14.1.e013623.34","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100325","article-title":"Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)","volume":"6","author":"Nakamura","year":"2021","journal-title":"ESMO Open"},{"key":"2026012218251179000_14.1.e013623.35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0291727","article-title":"Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours","volume":"18","author":"Maekawa","year":"2023","journal-title":"PLoS ONE"},{"key":"2026012218251179000_14.1.e013623.36","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-021-00147-6","article-title":"PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma","volume":"5","author":"Maekawa","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"2026012218251179000_14.1.e013623.37","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz003"},{"key":"2026012218251179000_14.1.e013623.38","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jtho.2018.04.010","article-title":"Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer","volume":"13","author":"Katz","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2026012218251179000_14.1.e013623.39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-84009-8","article-title":"Dissociated response and treatment outcome with immune checkpoint blockade in advanced cancer","volume":"14","author":"Guan","year":"2024","journal-title":"Sci Rep"},{"key":"2026012218251179000_14.1.e013623.40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0895"},{"key":"2026012218251179000_14.1.e013623.41","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"2026012218251179000_14.1.e013623.42","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat Commun"},{"key":"2026012218251179000_14.1.e013623.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.04.004"},{"key":"2026012218251179000_14.1.e013623.44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1482746","article-title":"Prognostic value of inflammatory markers NLR, PLR, LMR, dNLR, ANC in melanoma patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review","volume":"15","author":"Ou","year":"2024","journal-title":"Front Immunol"},{"key":"2026012218251179000_14.1.e013623.45","article-title":"Landscape of Microsatellite Instability Across 39 Cancer Types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2026012218251179000_14.1.e013623.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.519"},{"key":"2026012218251179000_14.1.e013623.47","doi-asserted-by":"crossref","first-page":"106807","DOI":"10.1016\/j.oraloncology.2024.106807","article-title":"Mutational landscape of oral mucosal melanoma based on comprehensive cancer genomic profiling tests in a Japanese cohort","volume":"152","author":"Ichimura","year":"2024","journal-title":"Oral Oncol"},{"key":"2026012218251179000_14.1.e013623.48","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0149"},{"key":"2026012218251179000_14.1.e013623.49","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24836-9","article-title":"Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds","volume":"12","author":"Alsaihati","year":"2021","journal-title":"Nat Commun"},{"key":"2026012218251179000_14.1.e013623.50","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-42437-x","article-title":"The secreted Ly6\/uPAR-related protein-1 suppresses neutrophil binding, chemotaxis, and transmigration through human umbilical vein endothelial cells","volume":"9","author":"Swamynathan","year":"2019","journal-title":"Sci Rep"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T02:25:25Z","timestamp":1769135125000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,22]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/jitc-2025-013623"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013623","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}